RecruitingNCT06702111
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in Adults: Clinical Outcome and Complications
Sponsor
The University of Hong Kong
Enrollment
1,000 participants
Start Date
Dec 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
To collect baseline and outcome data relating to all bone marrow, peripheral blood, cord blood hematopoietic stem cell transplants and therapies related to hematopoietic stem cell transplantation performed in Queen Mary Hospital.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Adult patients aged 18 years or older who received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Exclusion Criteria1
- participant who is unable to give informed consent in a prospective cohort.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06702111
Related Trials
Ivosidenib as Post-HSCT Maintenance for AML
NCT067074934 locations
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
NCT0666510011 locations
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
NCT040984459 locations